Alpelisib selectively inhibits the PI3Kα isoform and its effectiveness against tumors harboring PIK3CA mutations was initially established in several early phase studies, testing the combination of alpelisib with ET in patients with ER+ breast cancer [98, 100]. The gene discussed is ESR1; the disease is breast carcinoma.